CRO Study Tracking: How Sponsors Keep BE Studies and Filings on Time
How sponsors track outsourced BE studies and clinical trials against agreed milestones, measure CRO on-time performance and protect filing dates.
How sponsors track outsourced BE studies and clinical trials against agreed milestones, measure CRO on-time performance and protect filing dates.
CDMOs lose customers between sample dispatch and feedback. Where the communication gaps arise, what they cost, and how to close them.
Late reference products, hidden approval steps, disconnected CRO schedules and weak progress reporting can put regulatory filing dates at risk. Spot four early warning signs.
One product across 15 markets can create 60+ regulatory deadlines a year. See why spreadsheet-based registration tracking becomes an RA risk – and what programme discipline changes.
Walk into most mid-size pharmaceutical or chemical organisations and you’ll find no shortage of process infrastructure. Yet, evaluating true pharma project management maturity reveals a common disconnect: SOPs govern every stage-gate, trackers log milestones by the dozen, but tech transfers still slip and regulatory dates get pushed back. The gap between looking mature on paper…
API technology transfer needs technical understanding, quality oversight and clear ownership. Check four gaps before committing to CDMO scale-up milestones.
Project Management in Pharma and chemical projects span R&D, clinical or trial phases, manufacturing, quality control, regulatory approval, and distribution – each with strict timelines, specialized teams, and its own set of dependencies. That complexity is exactly why structured project management has become a strategic necessity for these industries rather than an optional discipline layered…
The chemical industry is undergoing a major transformation driven by innovation, regulatory pressure, cost optimization, and rising demand for specialized products. In this landscape, Contract Development and Manufacturing Organizations (CDMOs) have emerged as critical strategic partners. Rather than building every capability in-house, pharma and chemical companies increasingly lean on CDMO partners to move faster, reduce…